Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epix Looks To Partner With Path Now Clear For Vasovist Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Epix will file an NDA in mid-2008 following positive results from reevaluation of the vascular imaging agent.
Advertisement

Related Content

Epix Looks To Late-2008 Approval For Vasovist Following NDA Resubmission
Epix Looks To Late-2008 Approval For Vasovist Following NDA Resubmission
Epix To Advance COPD, Alzheimer’s Drugs
Epix To Advance COPD, Alzheimer’s Drugs
Epix Considers Selling Vasovist If Imaging Agent Clears FDA
Epix Considers Selling Vasovist If Imaging Agent Clears FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS067652

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel